Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of rufinamide in Lennox-Gastaut syndrome
2016-004953-34Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rufinamide in Lennox-Gastaut syndrome (LGS), sponsored by Eisai Co., Ltd. Primary endpoint: Treatment-emergent adverse events and serious adverse events.
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2016-004953-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004953-34.